Molecular diagnosis and monitoring of leukemia and lymphoma

Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023

Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma.

Leukemia·2017

Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis.

Leukemia·2016

A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma.

Leukemia·2016

Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation.

Bone marrow transplantation·2015

Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival.

Leukemia·2014

Functional substitution of imatinib-inactivated canonical oncoprotein BCR::ABL1 by overexpressed PLAG1 results in BCR::ABL1-independent resistance in blast phase of chronic myeloid leukemia.

Leukemia research·2026

Outpatient step-up dosing of teclistamab and talquetamab in relapsed or refractory.

Leukemia research·2026

Advances in diagnosis and treatment of angioimmunoblastic T-cell lymphoma.

Leukemia research·2026

Immune-mediated thrombosis in myeloproliferative neoplasms: Pathogenic pathways and clinical relevance.

Leukemia research·2026

HTLV-1 and ATL: Decoding Molecular Pathogenesis for Next-Generation Therapies.

Leukemia research·2026

Comparison allogeneic hematopoietic stem cell transplantation and chemotherapy for consolidation in acute lymphoblastic leukemia in a Colombian Cohort. A propensity score matching analysis.

Leukemia research·2026

Natural Products as Anti-Angiogenic Agents: Molecular Targets, Signaling Pathways, and Mechanistic Insights.

Current pharmaceutical design·2026

Outcomes of Percutaneous Transhepatic Biliary Drainage in Patients With Malignant Biliary Obstruction Receiving Palliative Care.

The American journal of hospice & palliative care·2026

Resistance to covalent Bruton's tyrosine kinase inhibitors in diffuse large B‑cell lymphoma: Molecular mechanisms and therapeutic implications (Review).

International journal of oncology·2026

Anti-RANKL antibody treatment mitigates subchondral bone loss and cartilage degeneration without affecting synovial inflammation in a mouse model of rotator cuff tear arthropathy.

Bone & joint research·2026

Spontaneous Tumor Lysis Syndrome in Refractory Metastatic Esophageal Adenocarcinoma Presenting With Septic Shock.

Cureus·2026

Chitosan-Coated Oleuropein Nanoliposomes Enable Dose-Sparing Suppression of Serum Inflammatory Markers in a TNF-α-Induced Vascular Inflammation Model.

ACS omega·2026

Related Experiment Videos

Molecular diagnosis and monitoring of leukemia and lymphoma

Related Concept Videos

Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684.

Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma.

Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis.

A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma.

Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation.

Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival.

Functional substitution of imatinib-inactivated canonical oncoprotein BCR::ABL1 by overexpressed PLAG1 results in BCR::ABL1-independent resistance in blast phase of chronic myeloid leukemia.

Outpatient step-up dosing of teclistamab and talquetamab in relapsed or refractory.

Advances in diagnosis and treatment of angioimmunoblastic T-cell lymphoma.

Immune-mediated thrombosis in myeloproliferative neoplasms: Pathogenic pathways and clinical relevance.

HTLV-1 and ATL: Decoding Molecular Pathogenesis for Next-Generation Therapies.

Comparison allogeneic hematopoietic stem cell transplantation and chemotherapy for consolidation in acute lymphoblastic leukemia in a Colombian Cohort. A propensity score matching analysis.

Natural Products as Anti-Angiogenic Agents: Molecular Targets, Signaling Pathways, and Mechanistic Insights.

Outcomes of Percutaneous Transhepatic Biliary Drainage in Patients With Malignant Biliary Obstruction Receiving Palliative Care.

Resistance to covalent Bruton's tyrosine kinase inhibitors in diffuse large B‑cell lymphoma: Molecular mechanisms and therapeutic implications (Review).

Anti-RANKL antibody treatment mitigates subchondral bone loss and cartilage degeneration without affecting synovial inflammation in a mouse model of rotator cuff tear arthropathy.

Spontaneous Tumor Lysis Syndrome in Refractory Metastatic Esophageal Adenocarcinoma Presenting With Septic Shock.

Chitosan-Coated Oleuropein Nanoliposomes Enable Dose-Sparing Suppression of Serum Inflammatory Markers in a TNF-α-Induced Vascular Inflammation Model.

Related Experiment Videos

Molecular diagnosis and monitoring of leukemia and lymphoma

Related Concept Videos

Related Articles